Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Hasbani Follows up the Death of Farah Kassab and Issues Two Decisions and Two Letters to the General Prosecution and the Order of Physicians

 
The Information Office of Deputy Prime Minister Health Minister Ghassan Hasbani issued the following statement:
 
In the context of following up the death of Farah Kassab after she underwent a cosmetic surgery in a specialized hospital in cosmetic surgeries,
 
Health Minister Ghassan Hasbani took the following actions:
 
  1. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in day hospitals or other cosmetic surgery clinics.
  2. The issuance of a decision on the prevention of  surgical operations that require a general anesthetic in Dr. Nader Saab hospital specialized in cosmetic surgery.
  3. The issuance of a letter to the Public Prosecutor to investigate into the death of Farah Kassab.
  4. The issuance of a letter to the Lebanese Order of Physicians in Beirut to conduct necessary investigations into the death of Farah Kassab, and give the Order a period of two weeks to clarify some technical medical points and answer questions asked by Health Minister concerning the death of the said woman.
 
These steps came to complete the immediate oral decision of Health Minister Ghassan Hasbani to cease operations in the said clinic after the woman's death, and the written decision issued Friday 2 June 2017 which stipulates the following:
 
  1. Surgeries that may cause complications that require intensive care like liposuction and other surgeries shall not performed in places other than specialized hospitals which include an intensive care division that holds a license form Health Ministry in accordance with due process.
  2. The doctor should explain to the patient the risks of the surgery, including the plastic surgery, and ask the patient to sign the Patient Right Form and the informed consent.
    3
ATC Name B/G Ingredients Dosage Form Price
B01AC06 NU-SEALS G Acetylsalicylic acid - 75mg 75mg Tablet, enteric coated 403,153 L.L
N07AA01 NEOSTIGMINE RENAUDIN G Neostigmine - 5mg/5ml 5mg/5ml Injectable solution 2,460,576 L.L
N02BF02 NERVAX G Pregabalin - 75mg 75mg Capsule 513,348 L.L
N02BF02 NEUREXAL G Pregabalin - 75mg 75mg Capsule 335,577 L.L
A04AA01 NAUSETRON G Ondansetron - 4mg/5ml 4mg/5ml Solution 958,608 L.L
N02BF02 NEUREXAL G Pregabalin - 75mg 75mg Capsule 637,365 L.L
A04AA01 NAUSETRON G Ondansetron - 4mg/5ml 4mg/5ml Solution 802,466 L.L
C01DA02 NITROGLICERINA BIOINDUSTRIA L.I.M. G Nitroglycerine - 50mg/50ml 50mg/50ml Injectable concentrate for solution 1,057,604 L.L
C01DA02 NITROJECT INJECTION G Nitroglycerine - 50mg/10ml 50mg/10ml Injectable solution 7,018,889 L.L
A04AA01 NOZAMET G Ondansetron - 4mg 4mg Film, orodispersible 3,234,181 L.L
N02BF02 NEUREXAL G Pregabalin - 25mg 25mg Capsule 321,754 L.L
A04AA02 NEOSET G Granisetron (HCl) - 3mg/3ml 3mg/3ml Injectable solution 405,840 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 10mg 10mg Tablet, scored 431,373 L.L
N02BG06 NEO-PAN G Nefopam HCl - 20mg/2ml 20mg/2ml Injectable solution 483,783 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 10mg 10mg Tablet, scored 431,373 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 20mg 20mg Tablet 822,432 L.L
C01DX16 NICORANDIL BIOGARAN G Nicorandil - 20mg 20mg Tablet 822,432 L.L
C09AA05 NORMOPRIL G Ramipril - 2.5mg 2.5mg Tablet 229,797 L.L
D06BA05 NEO SULFA G Sulfanilamide - 12g 12g Powder 151,022 L.L
C09AA05 NORMOPRIL G Ramipril - 5mg 5mg Tablet 474,376 L.L
C09AA05 NORMOPRIL G Ramipril - 10mg 10mg Tablet 599,354 L.L
J05AG01 NEPINE G Nevirapine - 200mg 200mg Tablet 5,921,678 L.L
B02BD02 NOVOEIGHT BioTech Turoctocog Alfa - 500IU 500IU Injectable powder for solution+diluent 29,783,973 L.L
B02BD02 NUWIQ BioTech Coagulation Factor VIII recombinant, human (Simoctogog alfa) - 500IU 500IU Injectable powder for solution+diluent 47,418,699 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 2mg 2mg (100KIU) Injectable powder for solution+diluent 110,192,512 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 1mg 1mg (50KIU) Injectable powder for solution+diluent 60,204,155 L.L
B02BD08 NOVOSEVEN RT BioTech Eptacog alfa (activated) recombinant - 5mg 5mg (250KIU) Injectable powder for solution+diluent 275,482,577 L.L
B02BX04 NPLATE BioTech Romiplostim - 250mcg 250mcg Injectable powder for solution 67,369,332 L.L
L03AA02 NEOGRASTIM 30 BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution 1,970,969 L.L
L03AA02 NEUTROMAX BioTech Filgrastim - 300mcg/ml 300mcg/ml Injectable solution 2,553,301 L.L
    3
Sitemap
© Copyrights reserved to Ministry of Public Health 2025